Bora Pharmaceuticals announced preliminary consolidated revenue of NT$1.716 billion for October, down 17.85% year-on-year, primarily due to exchange rate fluctuations affecting approximately NT$100 million. However, cumulative revenue for the first ten months reached NT$16.613 billion, up 6.57% year-on-year, demonstrating stable operational momentum. With continued expansion of its North American manufacturing footprint, analysts expect the company’s growth trajectory in the global pharmaceutical contract development and manufacturing organization (CDMO) market to accelerate into a new phase.
Bora highlighted that its Maryland-based injectable facility in the U.S. will continue to lead revenue growth in Q4. With high-standard sterile manufacturing processes and automated filling and packaging capabilities, the plant meets the strong local demand for injectable production in the U.S. The U.S. “pharmaceutical reshoring” policy and the trend toward supply chain security position Bora as one of the few Asian companies capable of providing full injectable CDMO services domestically, making this a key driver of medium- to long-term growth.
Beyond Maryland, Bora has been actively strengthening its North American capacity in recent years. In July, the company completed an expansion at its Canadian facility, introducing filling technology for dermatological medications and raising annual capacity to over 50 million doses. Bora also unveiled a mid-term development plan for its Maple Grove, Minnesota plant, which will add more than 100,000 square feet of manufacturing and packaging space, further solidifying its “integrated North American manufacturing” strategy.
Analysts note that U.S. demand for local sterile and injectable manufacturing is rising rapidly. Leveraging advanced automated processes and multinational integration capabilities, Bora is well-positioned to secure long-term CDMO contracts from major European and U.S. pharmaceutical companies. As North American capacity continues to come online, Q4 2025 through 2026 is expected to be a critical period for scaling Bora’s CDMO business.
Notably, Bora was recently honored with the “Overall Biotech Company of the Year” award at the Biotech Breakthrough Awards following the global pharmaceutical exhibition CPHI, making it one of the few Asian companies to receive this recognition. The award underscores the company’s comprehensive strength in maintaining stable manufacturing quality and a global service infrastructure, highlighting its leadership in biopharmaceutical manufacturing and international collaboration.
Overall, with U.S. “local pharmaceutical manufacturing” policies taking effect and the reshoring of North American supply chains accelerating, Bora has strategically positioned itself through capacity expansion and technological upgrades. Analysts expect that as its three North American sites gradually contribute output, they will serve as the main engine driving revenue growth through 2026.
Resource: 保瑞前十月營收年增6.57％ 北美製造鏈成未來成長主引擎
